At Week 104 , mean change from baseline in GmTSS was significantly lower for patients initially randomized to tocilizumab-MTX 4 mg/kg ( 0.58 ; p = 0.0025 ) or 8 mg/kg ( 0.37 ; p < 0.0001 ) than for patients initially randomized to placebo-MTX ( 1.96 ) .
